ANGLE Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

ANGLE şirketinin toplam hissedar öz sermayesi £24.5M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £33.0M ve £8.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£17.88m
Eşitlik	UK£24.51m
Toplam yükümlülükler	UK£8.48m
Toplam varlıklar	UK£32.98m

Son finansal sağlık güncellemeleri

Recent updates

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

Sep 27

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Mar 20

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

Dec 02

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Aug 11

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Feb 28

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Jul 16

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Aug 23

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

May 02

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?

Feb 14

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Dec 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AGL 'nin kısa vadeli varlıkları ( £23.6M ) kısa vadeli yükümlülüklerini ( £4.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: AGL şirketinin kısa vadeli varlıkları ( £23.6M ) uzun vadeli yükümlülüklerini ( £3.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AGL borçsuzdur.

Borcun Azaltılması: AGL şirketinin 5 yıl önce borç/öz sermaye oranı 3.7% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AGL şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: AGL serbest nakit akışı her yıl % 9.8 1.7 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/10 01:44
Gün Sonu Hisse Fiyatı	2025/01/10 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

ANGLE plc 6 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Samuel England	Berenberg
Navid Malik	Cavendish Historical (Cenkos Securities)
Lucy-Emma Mary Codrington-Bartlett	Edison Investment Research

ANGLE Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Forecast to breakeven in 2027

ANGLE plc Announces the Presentation of an Independent Study, Reporting on a Novel, Parsortix -Based Human Epidermal Growth Factor Receptor 2 (Her2) Workflow at the Prominent San Antonio Breast Cancer Symposium

Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR

New major risk - Share price stability

Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock